Allgulander C, Hackett D, Salinas E
Neurotec/Psychiatry, Huddinge University Hospital, Huddinge, Sweden.
Br J Psychiatry. 2001 Jul;179:15-22. doi: 10.1192/bjp.179.1.15.
Generalised anxiety disorder (GAD) has received less study than other anxiety disorders, particularly its long-term treatment.
To assess the efficacy and safety of venlafaxine extended release (ER) in patients with GAD.
A total of 541 out-patients, 18-86 years old, were recruited to this 24-week, placebo-controlled, double-blind study of three fixed doses (37.5, 75 and 150 mg/day) of venlafaxine ER.
All doses of venlafaxine ER showed efficacy superior to placebo, apparent from week 2, that was sustained throughout the 24-week study for the two higher doses. The discontinuation rate did not differ significantly among the treatment groups.
Venlafaxine ER is an effective and safe treatment for GAD for up to 6 months.
广泛性焦虑障碍（GAD）相比其他焦虑症所受到的研究较少，尤其是其长期治疗。
评估文拉法辛缓释剂（ER）治疗广泛性焦虑障碍患者的疗效和安全性。
总共招募了541名年龄在18至86岁之间的门诊患者，参与这项为期24周、安慰剂对照、双盲的研究，该研究涉及三种固定剂量（37.5、75和150毫克/天）的文拉法辛缓释剂。
所有剂量的文拉法辛缓释剂均显示出优于安慰剂的疗效，从第2周开始明显，对于两种较高剂量在整个24周的研究中疗效持续。各治疗组的停药率无显著差异。
文拉法辛缓释剂在长达6个月的时间里是治疗广泛性焦虑障碍的一种有效且安全的疗法。
